Managing drug interactions in HIV-infected adults with comorbid illness

CMAJ

Volumn 187, Issue 1, 2015, Pages 36-43

  Hughes, Christine A ^a,c   Tseng, Alice ^d,e   Cooper, Ryan ^b  

^a GI Diseases Research Unit   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Northern Alberta HIV Program   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; APIXABAN; ATAZANAVIR; CALCIUM CHANNEL BLOCKING AGENT; COBICISTAT; CYTOCHROME P450; DARUNAVIR PLUS RITONAVIR; FAMOTIDINE; FENTANYL; FLUOXETINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; NEUROLEPTIC AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RILPIVIRINE; RITONAVIR; RIVAROXABAN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; WARFARIN; CARDIOVASCULAR AGENT;

ADULT; AREA UNDER THE CURVE; BRADYCARDIA; COMORBIDITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERACTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TOXICITY; DYSLIPIDEMIA; DYSPEPSIA; EDEMA; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; LIVER TOXICITY; MUSCLE DISEASE; POLYPHARMACY; POST EXPOSURE PROPHYLAXIS; REVIEW; SEROTONIN SYNDROME; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASES; HIV INFECTIONS; MENTAL DISORDERS;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MENTAL DISORDERS;

EID: 84920579115     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.131626     Document Type: Review

References (75)

1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolesce nts. Rockville (MD): Department of Health and Human Services, AIDSinfo; updated 2014 May 1. Available: http://aidsinfo.nih.gov/guidelines/html/1/adult-And-Adolescent-treatment-guidelines/0 (accessed 2014 Sept. 8).
3. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9.
4. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542-53.
5. Goulet JL, Fultz SL, Rimland D, et al. Do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007;45:1593-601.
6. Nkhoma E, Vannappagari V, Mynepalli L, et al. Comorbidities and coinfections among HIV patients 50 years and older [abstract O-16]. First International Workshop on HIV & Aging; 2010 Oct. 4-5; Baltimore.
7. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011;66:2107-11.
8. Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother 2013;47:1429-39.
9. Koram N, Vannappargari V, Sampson T, et al. Comorbidity prevalence and i ts influence on non-ARV comedication burden among HIV positive patients [abstract 323]. IDWeek 2013 [conference]; 2013 Oct. 2-6; San Francisco.
10. Rathbun RC, Liedtke MD. Antiretroviral drug interactions: overview of i nteractions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 2011;3:745-81.
11. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008;42:1048-59.
12. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) [product monograph]. Mississauga (ON): Gilead Sciences Inc.; 2014.
13. Agarwala S, Eley T, Vilegas C, et al. Pharmacokinetic effect of famotidine on atazanavir with or without ritonavir in healthy subjects [abstract 11]. 6th International Workshop on Clini cal Pharmacology of HIV Therapy; 2005 Apr. 28-30; Quebec City.
14. Wang X, Boffito M, Zhang J, et al. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir wit h or without tenofovir in HIV-infected patients. AIDS Patient Care STDS 2011;25:509-15.
15. Chung E, Zhu L, Sims K, et al. An increase in atazanavir to 400 mg mitigates the effects of famotidine when given with ritonavir and tenofovir DF in HIV-infected patients [abstract P-14]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012 Apr. 16-18; Barcelona, Spain.
16. Van Heeswijk RP, Hoetelmans RM, Kest ens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers [abstract TUPDB01]. 4th International AIDS Society Conference o n HIV Pathogenesis, Treatment and Prevention; 2007 July 22-25; Sydney, Australia.
17. Agarwala S,Gray K,Eley T,et al. Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects [poster WePe3.3C08]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment 2005 July 24-27; Rio de Janeiro, Brazil.
18. Agarwala S, Gray K, Wang Y, et al. Pharmacokinetic effect of omeprazole on atazanavir with ritonavir in healthy subjects [abstract 658]. 12th Conference on Retroviruses an d Opportunistic Infections; 2005 Feb. 22-25; Boston.
19. Tomilo DL, Smith PF, Ogundele AB, et al. The effect of lansoprazole acid suppression on the pharmacokinetics of atazanavir in healthy volunteers [abstract A-1192]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec. 16-19; Washington.
20. Luber A, Brower R, Peloquin CA, et al. Steady-state pharmacokinetics of QD fosampren avir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg QD of omeprazole in healthy volunteers [abstract 36]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr. 20-22; Lisbon, Portugal.
21. Luber AD, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med 2007;8: 457-64.
22. Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol 201 1;51:368-77.
23. Antoniou T, Yoong D, Beique L, et al. Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. J A cquir Immune Defic Syndr 2005;39:126-8.
24. Kosel BW, Storey SS, Collier AC. Lack of interaction between atazanavir and lansoprazole. AIDS 2005;19:637-8.
25. P oirier J, Guiard-Schmid J, Bonnard P, et al. Proton pump inhibitors do not decrease atazanavir trough plasma concentrations in HIV-infected patients treated with ritonavir boosted atazanavir regimen (300/100 mg qd) [abstract H-1895]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec. 16-19; Washington.
26. Edurant (rilpivirine) [product monograph]. Toronto: Janssen Inc.; 2013.
27. Reyataz (atazanavir) [pr oduct monograph]. Montréal: Bristol-Myers Squibb Canada; 2013.
28. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-Administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66:1567-72.
29. Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr 2 013;64:45-50.
30. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemothe r 2010;54:4999-5003.
31. Bruce RD, Moody DE, Altice FL, et al. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Ph armacol 2013;6:249-69.
32. Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharm acol 2010; 66:977-85.
33. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999;91:681-5.
34. Cheng R, Greenall J, Koczmara C, et al. HIV postexposure prophylaxis and the need for drug interaction screening. Can J Hosp Pharm 2008;61:439-40.
35. Egan G, Hughes CA, A ckman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral drugs. Ann Pharmacother 2014;48:734-40.
36. Ancrenaz V. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol 2013;112:132-7.
37. Xu C, Desta Z. In vitro analysis and quantitative prediction of efavirenz inhibition on eight cytochrome enzymes. Drug Metab Pharmacokinet 2013;28:362-71.
38. Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78:143-53.
39. Puech R,Gagnieu MC,Planus C,et al. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir Br J Clin Pharmacol 2011 71 621-3.
40. Izzedine H, Launay-Vacher V, Deray G, et al. Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. Clin Pharmacol Ther 2004;75:362-3.
41. Sustiva (efavirenz) [product monograph]. Montréal: Bristol-Myers Squibb Canada; 2008.
42. Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother 2013;47:75-89.
43. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between queti apine and atazanavir-ritonavir in two patients. Pharmacotherapy 2009;29:1386-91.
44. Hantson P, Di Fazio V, Wallemacq P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. Drug Metab Lett 2010;4:7-8.
45. Aung GL, O'Brien JG, Tien PG, et al. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother 2010;44:1850-4.
46. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 2013;52:815-31.
47. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81.
48. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-77.
49. FDA drug safety communication: i nteractions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. Silver Spring (MD): US Food and Drug Administration; 2013. Available: www.fda.gov/Drugs/DrugSafety/ucm 293877.htm#sa (accessed 2014 Apr. 7).
50. Ahmed MH, Al-Atta Y, Hamad MA. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacot her 2012;13:1901-9.
51. Carr RA, Andre RJ, Bertz RJ, et al. Concomitant administration of ABT 378/ritonavir results in clinically important pharmacokinetic interaction with atorvastatin but not pravas tatin [abstract 334]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept. 17-20; Toronto.
52. Hoetelmans R, Lasure A, Koester A, et al. The effect of TMC114, a potent next-gener ation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics [poster H-865]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct. 30-Nov. 2; Washington.
53. Busti AJ , Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51:605-10.
54. Samineni D, Desai PB, Sallans L, et al. Steady state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012;52:922-31.
55. Kiser JJ, Gerber JG, Perdhomm e JA, et al. Drug drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008;47:570-8.
56. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin or rifabutin [abstract O-03]. 13th International Workshop on Clinical Pharmacology of HIV Therapy; 2012 Apr. 16-18; Barcelona, Spain.
57. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune De fic Syndr 2005;39:307-12.
58. Intelence (etravirine) [product monograph]. Toronto: Janssen Inc.; 2013.
59. Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 2010;50:1180-7.
60. Hogeland GW,Swindells S,McNabb JC,et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects Clin Pharmacol Ther 2007 81 69-75.
61. Sekar V, De Paepe E, De Marez T, et al. Pharma cokinetic interaction between darunavir (TMC 114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline [abstract P295]. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov . 12-16; Glasgow, Scotland.
62. van der Lee MJ, Blenke AA, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 20 07; 51:4098-104.
63. DeSilva KE, LeFlore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15:1281-5.
64. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of desipramine [abstract]. 11th International Conference on AIDS; 1996 July 7-12; Vancouver.
65. No rvir (ritonavir) [product monograph]. Saint-Laurent (QC): AbbVie Corporation; 2012.
66. Tornio A, Niemi M, Neuvonen PJ, et al. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clin ical implications. Trends Pharmacol Sci 2012;33:312-22.
67. Sevinsky H, Eley T, Yones C, et al. Effect of atazanavir with and without ritonavir on the pharmacokinetics of the CYP2C8 probe rosigl itazone in healthy subjects [abstract O5]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008 Apr. 7-9; New Orleans.
68. Sekar V, Spinosa-Guzman S, Meyvisch P, et al. Cocktail stud y to investigate the in-vivo drug interaction potential of darunavir co-Administered with low-dose ritonavir (DRV/r) on cytochrome P450 enzymes 2D6, 2C9 and 2C19 [abstract P23]. 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008 Apr. 7-9; New Orleans.
69. Welzen MEB, Van den Berk GEL, Hamers RL, et al. Interaction between antiretroviral drugs and acenocoumarol. Antivir Ther 2011;16:249-52.
70. Liedtke MD, Vanguri A, Rathbun RC. A probable interaction between warfarin and the antiretroviral TRIO study regimen. Ann Pharmacother 2012;46:e34.
71. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007;177:357-9.
72. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-7.
73. Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 2008; 28:945-9.
74. Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010; 50:1419-21.
75. Sheeha n NL, Kelly DV, Tseng AL, et al. Evaluation of HIV drug interaction websites. Ann Pharmacother 2003;37:1577-86.